Gene editing is transforming the treatment of inherited diseases, but efficient and precise gene insertion has often come at the expense of cell viability, stem cell fitness, and long-term durability. In this executive summary, Touchlight explores how Megabulb DNA (mbDNA™), a proprietary circular single-stranded DNA HDR donor, addresses key limitations associated with traditional viral donor systems such as AAV, including toxicity, payload constraints, manufacturing complexity, and safety concerns. The summary highlights preclinical and translational data demonstrating how mbDNA is engineered to support high-efficiency genome editing while minimizing cellular stress and preserving the long-term function of hematopoietic stem and progenitor cells (HSPCs).

Drawing on independent research from the University of Padova and CIEMAT, the report examines the performance of mbDNA in clinically relevant stem cell models, including its ability to support targeted gene insertion, maintain cellular function, and preserve genetically corrected cell populations over time. It also outlines how non-viral HDR donor technologies may enable safer, more scalable, and commercially viable gene therapy workflows, with compatibility across emerging delivery platforms such as electroporation and lipid nanoparticles (LNPs).

Download the full executive summary to explore the data behind mbDNA and its potential to help redefine the future of precision gene editing and genetic medicine.